Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, raised $70 million by offering 7 million shares at $10, below the range of $12 to $14. It had previously filed to offer 5.8 million shares at the same range....read more
Eight IPOs plan to raise $1.6 billion in the week ahead. Tech, biotech and China have been key drivers of 2018 IPO activity, and more of each are scheduled for the week ahead. Each of the three segments was hit particularly hard during the recent sell-off, but...read more
LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to...read more
US IPO Weekly Recap: IPOs are put through the ringer with 7 completed deals
Seven IPOs raised $1.1 billion, an active week given the market's volatility. Reflecting that backdrop, five of the seven five priced below the range, and two more postponed. Most had insider support. While the number of deals on the ...read more
It's only logical: Gene editing biotech LogicBio Therapeutics prices $70 million IPO below the range at $10
LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, raised $70 million by offering 7 million shares at $10, below the range of $12 to $14. It had previously filed to offer 5.8 million shares at the same range....read more
US IPO Week Ahead: SolarWinds headlines 8-IPO week with tech, biotech and China
Eight IPOs plan to raise $1.6 billion in the week ahead. Tech, biotech and China have been key drivers of 2018 IPO activity, and more of each are scheduled for the week ahead. Each of the three segments was hit particularly hard during the recent sell-off, but...read more
Gene editing biotech LogicBio Therapeutics sets terms for $75 million IPO
LogicBio Therapeutics, a preclinical gene editing biotech developing therapies for rare diseases, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to...read more